(Reuters) – Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they added.
The all-cash transaction is subject to adjustment for ProfoundBio’s closing net debt and transaction expenses.
(Reporting by Elviira Luoma, editing by Terje Solsvik)
Comments